Enhancement of endocannabinoid signaling and the pharmacotherapy of depression
- Author(s): Mangieri, RA
- Piomelli, D
- et al.
Published Web Locationhttps://doi.org/10.1016/j.phrs.2007.09.003
Cannabinoids are well known modulators of mood and emotional behavior. Current research supports a role for endocannabinoid signaling in the treatment of depression. Changes in levels of the cannabinoid CB1receptor or the endogenous CB1receptor ligands, anandamide and 2-AG, are observed both in humans suffering from depression and in animal models of depression, and experimental manipulation of CB1receptor signaling has also been shown to affect emotional reactivity in rodents. Importantly, inhibitors of anandamide inactivation have demonstrated efficacy in enhancing stress-coping and mood-related behavior. This article will review these areas of research, highlighting the potential of endocannabinoid metabolism modulators as therapeutics for the treatment of depression. © 2007 Elsevier Ltd. All rights reserved.
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.